Allergens are not pathogens: Why immunization against allergy differs from vaccination against infectious diseases

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 3, 2014, Pages 703-707

  Weiss, Richard ^a   Scheiblhofer, Sandra ^a   Thalhamer, Josef ^a  

^a UNIVERSITY OF SALZBURG   (Austria)

Author keywords

Allergy vaccines; DNA vaccine; Hygiene hypothesis; Infectious diseases; mRNA vaccine; Natural immunity; Prevention; Prophylactic; Safety; Type I allergy

Indexed keywords

ALLERGEN; DNA VACCINE; MRNA VACCINE; PLASMID DNA; RECOMBINANT ALLERGEN; RNA VACCINE; UNCLASSIFIED DRUG;

ALLERGY; ANTIBODY TITER; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION; LOW DRUG DOSE; NONHUMAN; NOTE; PANDEMIC; PHASE 1 CLINICAL TRIAL (TOPIC); SENSITIZATION; STUDY DESIGN; T LYMPHOCYTE; VACCINATION; HYPERSENSITIVITY; IMMUNOLOGY; PROCEDURES;

ALLERGENS; HUMANS; HYPERSENSITIVITY; VACCINATION; VACCINES, DNA;

EID: 84898490601     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27183     Document Type: Note

References (45)

1. Tuohy VK, Jaini R. Prophylactic cancer vaccination by targeting functional non-self. Ann Med 2011; 43: 356-65; PMID:21651440; http://dx.doi.org/10.3109/07853890.2011.565065
2. Finn OJ, Forni G. Prophylactic cancer vaccines. Curr Opin Immunol 2002; 14:172 -7; PMID:11869888; http://dx.doi.org/10.1016/ S0952 -7915(02) 00317-5
3. McCarron MO, Nicoll JA. Cerebral amyloid angiopathy and thrombolysis -related intracerebral haemorrhage. Lancet Neurol 2004; 3: 484-92; PMID:15261609; http://dx.doi.org/10.1016/S1474-4422(04) 00825 -7
4. Shimada M, Abe S, Takahashi T, Shiozaki K, Okuda M, Mizukami H, Klinman DM, Ozawa K, Okuda K. Prophylaxis and treatment of Alzheimer's disease by delivery of an adeno-associated virus encoding a monoclonal antibody targeting the amyloid Beta protein. PLoS One 2013; 8:e57606; PMID:23555563; http://dx.doi.org/10.1371/journal.pone.0057606
5. Li A, Escher A. DNA Immunotherapies for Type 1 Diabetes. In: Escher A, ed. Endocrinology and Metabolism: Type 1 Diabetes, 2013.
6. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008; 9:776-88; PMID:18781156; http://dx.doi.org/10.1038/nrg2432
7. Geall AJ, Mandl CW, Ulmer JB. RNA: the new revolution in nucleic acid vaccines. Semin Immunol 2013; 25:152-9; PMID:23735226; http://dx.doi.org/10. 1016/j.smim.2013.05.001
8. Redding L, Weiner DB. DNA vaccines in veterinary use. Expert Rev Vaccines 2009; 8:1251-76; PMID:19722897; http://dx.doi.org/10.1586/erv.09.77
9. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: current progress. Clin Infect Dis 2011; 53: 296 -302; PMID:21765081; http://dx.doi.org/10.1093/cid/cir334
10. Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, McTamney PM, Pearce MB, Yassine HM, Boyington JC, et al.; VRC 306 Study Team. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011; 11: 916 -24; PMID:21975270; http://dx.doi.org/10.1016/ S1473 -3099(11) 70240 -7
11. Ledgerwood JE, Zephir K, Hu Z, Wei CJ, Chang L, Enama ME, Hendel CS, Sitar S, Bailer RT, Koup RA, et al.; VRC 310 Study Team. Prime -boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis 2013; 208: 418-22; PMID:23633407; http://dx.doi.org/10.1093/infdis/jit180
12. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol 2009; 21: 346 -51; PMID:19500964; http://dx.doi.org/10.1016/j.coi.2009.05.016
13. Weiss R, Scheiblhofer S, Roesler E, Ferreira F, Thalhamer J. Prophylactic mRNA vaccination against allergy. Curr Opin Allergy Clin Immunol 2010; 10:567-74; PMID:20856111; http://dx.doi.org/10.1097/ACI.0b013e32833fd5b6
14. Ozawa S, Mirelman A, Stack ML, Walker DG, Levine OS. Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review. Vaccine 2012; 31: 96 -108; PMID:23142307; http://dx.doi.org/10.1016/j.vaccine.2012.10.103
15. Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, &. Immunology 2011; 106: S12-6
16. Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, FitzGerald JM. Economic burden of asthma: a systematic review. BMC Pulm Med 2009; 9:24; PMID:19454036; http://dx.doi.org/10.1186/1471-2466 -9 -24
17. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, Nelson H, Akdis CA. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013; 131:1288-96, e3; PMID:23498595; http://dx.doi.org/10.1016/j.jaci.2013.01.049
18. Fernández-Rivas M, Bolhaar S, González-Mancebo E, Asero R, van Leeuwen A, Bohle B, Ma Y, Ebner C, Rigby N, Sancho AI, et al. Apple allergy across Europe: how allergen sensitization profiles determine the clinical expression of allergies to plant foods. J Allergy Clin Immunol 2006; 118: 481-8; PMID:16890775; http://dx.doi.org/10.1016/j.jaci.2006.05.012
19. Valenta R, Campana R, Marth K, van Hage M. Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. J Intern Med 2012; 272:144-57; PMID:22640224; http://dx.doi.org/10.1111/j.1365 -2796.2012.02556.x
20. Weiss R, Scheiblhofer S, Roesler E, Weinberger E, Thalhamer J. mRNA vaccination as a safe approach for specific protection from type I allergy. Expert Rev Vaccines 2012; 11:55-67; PMID:22149709; http://dx.doi.org/10.1586/ erv.11.168
21. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17:1055-65; PMID:20463105; http://dx.doi.org/10.1128/CVI.00131-10
22. Titball RW. Vaccines against intracellular bacterial pathogens. Drug Discov Today 2008; 13:596-600; PMID:18598915; http://dx.doi.org/10.1016/j. drudis.2008.04.010
23. Gabler M, Scheiblhofer S, Kern K, Leitner WW, Stoecklinger A, Hauser-Kronberger C, Alinger B, Lechner B, Prinz M, Vrtala S, et al. Immunization with a low-dose replicon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitization. J Allergy Clin Immunol 2006; 118: 734-41; PMID:16950295; http://dx.doi.org/10.1016/j.jaci.2006.04.048
24. Pulsawat P, Pitakpolrat P, Prompetchara E, Kaewamatawong T, Techakriengkrai N, Sirivichayakul S, Buranapraditkun S, Hannaman D, Ruxrungtham K, Jacquet A. Optimization of a Der p 2 -based prophylactic DNA vaccine against house dust mite allergy. Immunol Lett 2013; 151: 23-30; PMID:23396105; http://dx.doi.org/10.1016/j.imlet.2013.01.013
25. Roesler E, Weiss R, Weinberger EE, Fruehwirth A, Stoecklinger A, Mostböck S, Ferreira F, Thalhamer J, Scheiblhofer S. Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. J Allergy Clin Immunol 2009; 124:1070-7, e1-11; PMID:19665781; http://dx.doi.org/10.1016/j.jaci.2009.06.036
26. Zinkernagel RM. Immunological memory ≠ protective immunity. Cell Mol Life Sci 2012; 69:1635-40; PMID:22481438; http://dx.doi.org/10.1007/s00018-012- 0972-y
27. Smith KA, Gray NJ, Cheek E, Saleh F, Lavender J, Frew AJ, Kern F, Tarzi MD. Characterisation of CD154+ T cells following ex vivo birch allergen stimulation defines a close relationship between T cell subsets in healthy volunteers. BMC Immunol 2013; 14:14; PMID:23521868; http://dx.doi.org/10.1186/ 1471-2172 -14 -14
28. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, Thunberg S, Deniz G, Valenta R, Fiebig H, et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004; 199:1567-75; PMID:15173208; http://dx.doi.org/10.1084/jem.20032058
29. Van Overtvelt L, Wambre E, Maillère B, von Hofe E, Louise A, Balazuc AM, Bohle B, Ebo D, Leboulaire C, Garcia G, et al. Assessment of Bet v 1-specific CD4+ T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers. J Immunol 2008; 180: 4514 -22; PMID:18354173
30. Bullens DM, De Swerdt A, Dilissen E, Kasran A, Kroczek RA, Cadot P, Casaer P, Ceuppens JL. House dust mite-specific T cells in healthy non-atopic children. Clin Exp Allergy 2005; 35:1535-41; PMID:16393318; http://dx.doi.org/ 10.1111/j.1365 -2222.2005.02352.x
31. Romagnani S. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 2004; 112: 352-63; PMID:15196202; http://dx.doi.org/10.1111/j.1365 -2567.2004.01925.x
32. Brooks C, Pearce N, Douwes J. The hygiene hypothesis in allergy and asthma: an update. Curr Opin Allergy Clin Immunol 2013; 13: 70 -7; PMID:23103806; http://dx.doi.org/10.1097/ACI.0b013e32835ad0d2
33. Pei Y, Geng S, Liu L, Yan F, Guan H, Hou J, Chen Y, Wang B, An X. Fel d 1-airway inflammation prevention and treatment by co -immunization vaccine via induction of CD4+ CD25-Foxp3+ Treg cells. Hum Vaccin Immunother 2013; 9: 1019-31; PMID:23324570; http://dx.doi.org/10.4161/hv.23518
34. Jin H, Kang Y, Zhao L, Xiao C, Hu Y, She R, Yu Y, Du X, Zhao G, Ng T, et al. Induction of adaptive T regulatory cells that suppress the allergic response by coimmunization of DNA and protein vaccines. J Immunol 2008; 180:5360 -72; PMID:18390718
35. Weinberger EE, Isakovic A, Scheiblhofer S, Ramsauer C, Reiter K, Hauser-Kronberger C, Thalhamer J, Weiss R. The influence of antigen targeting to subcellular compartments on the anti -allergic potential of a DNA vaccine. Vaccine 2013; Forthcoming; PMID:23954383; http://dx.doi.org/10.1016/j.vaccine. 2013.08.005
36. Thalhamer T, Dobias H, Stepanoska T, Pröll M, Stutz H, Dissertori O, Lackner P, Ferreira F, Wallner M, Thalhamer J, et al. Designing hypoallergenic derivatives for allergy treatment by means of in silico mutation and screening. J Allergy Clin Immunol 2010; 125: 926-34, e10; PMID:20371399; http://dx.doi.org/10.1016/j.jaci.2010.01.031
37. Bauer R, Scheiblhofer S, Kern K, Gruber C, Stepanoska T, Thalhamer T, Hauser-Kronberger C, Alinger B, Zoegg T, Gabler M, et al. Generation of hypoallergenic DNA vaccines by forced ubiquitination: preventive and therapeutic effects in a mouse model of allergy. J Allergy Clin Immunol 2006; 118: 269-76; PMID:16815165; http://dx.doi.org/10.1016/j.jaci.2006.03.033
38. NCT01707069. A Safety and Immunogenicity Phase I Study of CryJ2-DNA -Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid. 2012: http://clinicaltrials.gov/show/NCT01707069.
39. Scheiblhofer S, Gabler M, Leitner WW, Bauer R, Zoegg T, Ferreira F, Thalhamer J, Weiss R. Inhibition of type I allergic responses with nanogram doses of replicon -based DNA vaccines. Allergy 2006; 61: 828-35; PMID:16792580; http://dx.doi.org/10.1111/j.1398 -9995.2006.01142.x
40. Jankovic D, Kullberg MC, Feng CG, Goldszmid RS, Collazo CM, Wilson M, Wynn TA, Kamanaka M, Flavell RA, Sher A. Conventional T-bet(+) Foxp3(-) Th1 cells are the major source of host-protective regulatory IL -10 during intracellular protozoan infection. J Exp Med 2007; 204: 273-83; PMID:17283209; http://dx.doi.org/10.1084/jem.20062175
41. Gabrysová L, Nicolson KS, Streeter HB, Verhagen J, Sabatos-Peyton CA, Morgan DJ, Wraith DC. Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells. J Exp Med 2009; 206:1755-67; PMID:19635862; http://dx.doi.org/10.1084/jem.20082118
42. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL -10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007; 120:707-13; PMID:17681368; http://dx.doi.org/10.1016/j.jaci.2007.06.013
43. Marenholz I, Kerscher T, Bauerfeind A, Esparza-Gordillo J, Nickel R, Keil T, Lau S, Rohde K, Wahn U, Lee YA. An interaction between filaggrin mutations and early food sensitization improves the prediction of childhood asthma. J Allergy Clin Immunol 2009; 123:911-6; PMID:19348926; http://dx.doi.org/10.1016/ j.jaci.2009.01.051
44. Kulig M, Bergmann R, Klettke U, Wahn V, Tacke U, Wahn U. Natural course of sensitization to food and inhalant allergens during the first 6 years of life. J Allergy Clin Immunol 1999; 103:1173-9; PMID:10359902; http://dx.doi.org/10.1016/S0091-6749(99) 70195-8
45. Hatzler L, Panetta V, Lau S, Wagner P, Bergmann RL, Illi S, Bergmann KE, Keil T, Hofmaier S, Rohrbach A, et al. Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever. J Allergy Clin Immunol 2012; 130: 894-901, e5; PMID:22841010; http://dx.doi.org/ 10.1016/j.jaci.2012.05.053